Compare Diageo plc (DEO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Johnson & Johnson — how do they compare? Diageo plc trades at $86.83 (market cap $47.67B), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 13× Diageo plc's market cap, and Diageo plc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Johnson & Johnson for 129 Days on average.
| DEO | JNJ | |
|---|---|---|
Market Cap | $47.67B | $618.09B |
Volume | 893,372 | 6,050,983 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $278.43 |
52-Week Low | $72.47 | $186.00 |
Typical Hold Time | 66 Days | 129 Days |
Enterprise Value | $68.09B | $646.37B |
Dividend Yield | 2.3% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical signals from moving averages. The company shows strong profitability with 59.47% gross margins and has beaten earnings estimates in the last three quarters. Recent developments include a new CFO appointment and marketing initiatives across key brands. The stock faces headwinds from declining 2026 revenue projections but maintains solid cash flow generation.
DEO presents a mixed outlook with analyst consensus leaning bullish (49% buy ratings) but facing execution risks in its US turnaround. The stock's premium valuation (P/E 27.9) requires sustained earnings growth, while regulatory challenges in India and competitive pressures warrant monitoring. Near-term catalysts include dividend payments and brand revitalization efforts.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
